Summer Sale! Save 25%
Free Express Shipping
Sale Ends: 07/18
Uses
Side effects
Interactions
Precautions
How Ludiomil works
- Maprotiline (Ludiomil) hydrochloride tab lets are indicated for the treatment of depressive illness in patients with depressive neurosis (dysthymic disorder) and manic depressive illness, depressed type (major depressive disorder).
- Maprotiline is also effective for the relief of anxiety associated with depression.
- The following adverse reactions have been noted with maprotiline and are generally similar to those observed with tricyclic antidepressants.
- Cardiovascular: Rare occurrences of hypotension, hypertension, tachycardia, palpitation, arrhythmia, heart block, and syncope have been re ported with maprotiline.
- Psychiatric: Nervousness (6%), anxiety (3%), insomnia (2%), and agitation (2%); rarely, confusional states (especially in the elderly), hallucinations, disorientation, delusions, restlessness, nightmares, hypomania, mania, exacerbation of psychosis, de crease in memory, and feelings of unreality
- Close super vision and careful adjustment of dosage are required when administering maprotiline concomitantly with anticholinergic or sympathomimetic drugs because of the possibility of additive atropine like effects.
- Concurrent administration of maprotiline with electro shock therapy should be a voided because of the lack of experience in this area.
- Caution should be exercised when administering maprotiline to hyperthyroid patients or those on thyroid medication because of the possibility of enhanced potential for cardiovascular toxicity of maprotiline.
- Maprotiline should be used with caution in patients receiving guanethidine or similar agents since it may block the pharmacologic effects of these drugs.
- The risk of seizures may be increased when maprotiline is taken concomitantly with phenothiazines or when the dosage of benzodiazepines is rapidly tapered in patients receiving maprotiline.
- Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic an tidepressants.
- Adjustment of the dos age of maprotiline hydrochloride may therefore be necessary in such cases.
- The possibility of suicide in seriously depressed patients is inherent in their illness and may persist until significant remission occurs.
- Therefore, patients must be carefully supervised during all phases of treatment with maprotiline, and prescriptions should be written for the smallest number of tablets consistent with good patient management.
- Hypomanic or manic episodes have been known to occur in some patients taking tricyclic antidepressant drugs, particularly in patients with cyclic disorders.
- Such occurrences have also been noted, rarely, with maprotiline.
